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Abstract
The use of sirolimus (SRL) in combination with full doses of
cyclosporin A (CsA) results in reduced one-year kidney allograft
function, which is associated with shorter long-term allograft sur-
vival. We determined the effect of reduced CsA exposure on graft
function in patients receiving SRL and prednisone. Ninety recipi-
ents of living kidney transplants receiving SRL (2 mg/day, po) were
compared to 35 recipients receiving azathioprine (AZA, 2 mg kg-1
day-1, po). All patients also received CsA (8-10 mg kg-1 day-1, po)
and prednisone (0.5 mg kg-1 day-1). Efficacy end-point was a com-
posite of biopsy-confirmed acute rejection, graft loss, or death at
one year. Graft function was measured by creatinine, creatinine
clearance, and graft function deterioration between 3 and 12 months
(∆1/Cr). CsA concentrations in patients receiving SRL were 26%
lower. No differences in one-year composite efficacy end-point
were observed comparing SRL and AZA groups (18 vs 20%) or in
the incidence of biopsy-proven acute rejection (14.4 and 14.3%).
There were no differences in mean ± SD creatinine (1.65 ± 0.46 vs
1.60 ± 0.43 mg/dl, P = 0.48) or calculated creatinine clearances (61 ±
15 vs 62 ± 13 ml/min, P = 0.58) at one year. Mean ± SD ∆1/Cr (-11 ±
17 vs -14 ± 15%, P = 0.7) or the percentage of patients with >20% (26
vs 31%, P = 0.6) or >30% ∆1/Cr (19 vs 17%, P = 1) did not differ
between the two groups. The use of 2-mg fixed oral doses of SRL
and reduced CsA exposure was effective in preventing acute rejec-
tion and preserving allograft function.
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Introduction
Two phase III, large, prospective, ran-
domized, multicenter, double-blind interna-
tional clinical trials have shown that sirolimus
(2 and 5 mg) in combination with full doses
of cyclosporin (CsA) and corticosteroids
reduces the incidence, severity, and need of
antibody therapy to treat acute rejection epi-
sodes compared to azathioprine (AZA) (1) or
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placebo (2). However, patients receiving
sirolimus showed impaired allograft function
6 and 12 months after transplantation, meas-
ured by either serum creatinine or calculated
creatinine clearances. Since sirolimus is a
critical-dose drug and has no nephrotoxic
effects of its own, the effect on graft func-
tion has been attributed to pharmacokinetic
and pharmacodynamic interactions between
sirolimus and CsA, increasing the suscepti-
bility of allografts to CsA-associated nephro-
toxic effects (3).
Impaired graft function at one year has
been associated with inferior long-term al-
lograft survival (4). Hence, strategies to
improve graft function using sirolimus/CsA
drug combinations are required (5). One
approach is to withdraw CsA 3 months after
transplantation, which has resulted in lower
blood pressure and improved calculated glo-
merular filtration rate at one year compared
to patients who continue to receive the
sirolimus/CsA combination (63 vs 57 ml/
min, P < 0.0001) (6). Although higher doses
of sirolimus were used after CsA withdraw-
al, a higher incidence of rejection was ob-
served (9.8 vs 4.2%, P = 0.035) along with
a higher incidence of thrombocytopenia and
hypokalemia. Abnormal liver function tests
were also observed, leading to an overall
higher rate of drug discontinuation (27 vs
18%, P = 0.028).
Since sirolimus and CsA show synergis-
tic effects both in vitro and in vivo (7),
another strategy to maintain the efficacy of
the CsA/sirolimus combination while pre-
serving renal function is to use reduced CsA
doses and exposures. However, the time and
magnitude of dose reduction have not been
systematically investigated (8,9). We ana-
lyzed here the effectiveness of the use of
initial full doses of CsA, with reduction of
CsA exposure one month after transplanta-
tion, in patients receiving 2-mg fixed daily
doses of sirolimus and prednisone, com-
pared with standard triple therapy. Also, we
correlated blood concentrations of CsA and
sirolimus with graft function at one year.
Subjects and Methods
Population
Between June 13, 1999 and October 8,
2000, 70 recipients of one-haplotype living
related kidney allografts were enrolled in a
single center, open label, randomized trial
comparing sirolimus (N = 35) versus AZA
(N = 35) as part of a CsA microemulsion and
prednisone immunosuppressive regimen. In
a concomitant multicenter, international,
single arm trial, 55 recipients of fully mis-
matched living related or unrelated allografts
also received a combination of sirolimus,
CsA microemulsion and prednisone. Patients
with end-stage renal disease, 13 years of age
or older, weighing 40 kg or more, all first
recipients of a kidney graft and with a nega-
tive T cell crossmatch, were eligible for
inclusion in both trials. Women of childbear-
ing potential were required to have a negative
pregnancy test before administration of the
study medication and to practice medically
approved birth control throughout the study
and for 3 months following discontinuation
of sirolimus. The protocol also required the
patients to have total white blood cell count
≥4.0 x 109/l, platelet count ≥100.0 x 109/l,
fasting cholesterol ≤350 mg/dl (≤9.1 mmol/
l) and/or fasting triglycerides ≤500 mg/dl
(≤5.65 mmol/l) during a pretransplant screen-
ing evaluation. High-risk patients deemed to
receive antibody induction (retransplants,
reactive antibody panel ≥50%, pediatric re-
cipients under 12 years of age) were ex-
cluded from the study. Patients were also
excluded if they had evidence of systemic
infection, a history of clinically significant
cardiac abnormalities or malignancy within
10 years of enrollment into the study and had
received treatment with an investigation agent
within 4 weeks of sirolimus administration.
Patients were not allowed to participate in the
trial if they were receiving any immunosup-
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pressive agent before transplantation or any
known cytochrome P450 inducers/inhibi-
tors, including terfenadine, cisapride, aste-
mizole, or pimozide. Patients with abnormal
chest radiography findings, known hyper-
sensitivity to macrolides or those who re-
quired antibody induction therapy were also
excluded. Prophylaxis for Pneumocystis
carinii pneumonia with trimethoprim-sulfa-
methoxazole was mandatory for all patients
during the 12-month treatment period. Pro-
phylaxis for cytomegalovirus infection was
also mandatory in cytomegalovirus-negative
patients who had received a kidney from a
cytomegalovirus-positive donor. These pa-
tients were required to take acyclovir for 3
months after transplantation. The local medi-
cal Ethics Committee approved all the proto-
cols and the studies were performed in ac-
cordance with the Declaration of Helsinki
and U.S. Food and Drug Administration
guidelines for good clinical practice. All pa-
tients signed a written informed consent
after they had been informed about the nature
and details of the studies.
Immunosuppressive treatment and
monitoring
Prior to graft revascularization all patients
received 1 g methylprednisolone. Within 24
h after transplant surgery, the patients re-
ceived an initial CsA dose of 8 to 10 mg/day
twice daily, 0.5 mg kg-1 day-1 prednisone up
to a maximum of 30 mg/day, and AZA (2 mg
kg-1 day-1) or sirolimus (a 6-mg loading dose
followed by a 2-mg fixed daily dose of
sirolimus, 1 mg/ml; Wyeth-Ayerst Research,
Radnor, PA, USA), administered 4 h after the
morning CsA dose. Blood CsA and sirolimus
concentrations were measured at weeks 1,
2, 4, 8, 12, 24, 36, and 52. Doses of CsA
were adjusted to keep trough whole blood
CsA concentrations between 200 and 400
ng/ml during the first 4 weeks, between 150
and 300 ng/ml from week 5 to 12, and
between 100 to 200 ng/ml thereafter. After
the fourth post-transplant week, patients
receiving sirolimus had their CsA doses ad-
justed to keep blood concentrations within
the lower range of the therapeutic window,
in contrast to patients receiving AZA who
had their CsA doses adjusted to the upper
level.
Efficacy analysis
Since all patients followed the same con-
centration-controlled CsA-based immuno-
suppressive regimen, we pooled together all
patients who received sirolimus (N = 90) and
compared them with those who received
AZA (N = 35). All patients were followed for
12 months and an intention-to-treat analysis
was used to assess efficacy failure, defined
as the composite of biopsy-proven acute
rejection, graft loss or death at 12 months. All
episodes of graft dysfunction were investi-
gated and a core biopsy was performed
whenever indicated. A local pathologist graded
the histological diagnoses according to the
1997 BANFF criteria (10). Biopsy-proven
acute rejection episodes were treated initially
with methylprednisolone, 0.5 to 1 g for 3 to
5 days. Biopsy-proven steroid-resistant acute
rejections were treated with OKT3, a first
dose of 5 mg followed by 2.5-mg daily doses
to keep CD3-positive cells below 10/mm3.
Time to and histological grade of first bi-
opsy-confirmed acute rejection were also
analyzed. Graft loss was defined as physical
loss due to nephrectomy, functional loss
requiring maintenance dialysis for more
than 8 weeks, or death with a functioning
graft.
Graft function
To understand the impact of the continu-
ous use of sirolimus on graft function of
patients receiving CsA, only patients receiv-
ing either sirolimus and CsA or AZA and CsA
up to 12 months post-transplant (per-proto-
col population) were used for the analysis of
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graft function. First we compared serum
creatinine values at months 1, 2, 3, 4, 6, 9,
and 12 and calculated creatinine clearances
at 3, 6 and 12 months, using the Cockcroft-
Gault formula (11). Second, we investigated
the magnitude of loss of function between 3
and 12 months post-transplant using the ∆1/
Cr, a strong time-dependent predictor of
graft failure (12). Baseline graft function was
assessed during the first 3 months after
transplantation using the mean of the 3 low-
est creatinine values. In each group, graft
function deterioration at 12 months was
determined by comparing mean percent ∆1/
Cr and the percentage of patients showing
higher than -20% or -30% ∆1/Cr at 12
months.
Bioanalytical methods
Whole blood CsA concentrations were
determined with the AxSYM CsA fluores-
cence polarization immunoassay kit (Abbott
Laboratories, Abbott Park, IL, USA), ac-
cording to manufacturer directions. Perfor-
mance was assessed on the basis of a 3-point
quality control concentration range of low
(70 ng/ml), intermediate (300 ng/ml), and
high (600 ng/ml) concentrations. Whole blood
sirolimus concentrations were measured using
an HPLC method adapted from Maleki et al.
(13). Briefly, 75 µl of internal standard solu-
tion (desmethoxysirolimus) was added to
500 µl of whole blood calibrators and clinical
samples. Sirolimus was extracted using 1 ml
5% ZnSO4 and 1 ml acetone. Two hundred
microliters 100 mM NaOH and 2 ml 1-
chlorobutane were added to the superntants,
vortexed and centrifuged. The upper organic
layer (2 ml) was pipetted off and evaporated
to dryness. Sample extracts were reconsti-
tuted with 150 µl of an acetonitrile/water
(70:30) mixture and 500 µl hexane was
added, vortexed and centrifuged. The hex-
ane layer was pipetted off and 50 µl was
injected into a reverse-phase C18 column
(50ºC, flow rate of 1.0 ml/min). Ultraviolet
detection was performed at 278 nm and
quantification of sirolimus was based on a
peak area ratio. Analytical recovery of 93.8
to 109.0% was observed throughout the
linear range of the assay (2.5-150.0 ng/ml).
The lower limit of quantification was set at
2.5 ng/ml (coefficient of variation = 9.6%).
The intra-assay precision ranged from 2 to
15%, and the interassay precision ranged
from 5.5 to 9.3%.
Statistical analysis
The sample size was determined using
the Cochran and Cox formula (14). For the
purpose of this study we estimated that the
acute rejection rates without and with the use
of sirolimus at 3 months would be 32 and
4%, respectively, according to data already
available from the global study (2). With a
significance level of 0.05 in a two-sided test,
and a power of 0.80, the required number of
patients in each group was 25, for a total of
50 patients. All patients were followed for 12
months. To determine whether reduced ex-
posure to CsA was effective an intention to
treat analysis was used to compare the inci-
dence of biopsy-proven acute rejection, graft
loss or death observed in 90 patients receiv-
ing sirolimus and in 35 patients receiving
AZA at 12 months. To determine whether
reduced exposure to CsA preserved graft
function, only patients who received the
sirolimus, CsA, and prednisone combination
during the entire 12-month follow-up period
were included and compared with patients
who received AZA, CsA, and prednisone.
Continuous variables were analyzed by the
unpaired Student t-test or by analysis of
variance. Categorical variables were ana-
lyzed by the chi-square or Fisher exact test
depending on the number of observations.
Whisker and box plots and the chi-square
test were used to show and compare blood
sirolimus concentrations, creatinine and
creatinine clearances. Multiple regression
analyses were used to correlate CsA and
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sirolimus concentration with graft function
at one year. Statistical analysis was done
using the SPSS 7.5 software (SPSS Inc.).
Differences were considered significant at P
< 0.05.
Results
Demographics
The demographic characteristics of this
patient population, as shown in Table 1, are
representative of our general adult transplant
population. Mean age was 38.1 ± 10.8 years,
mean weight 64.9 ± 9.6 kg, and mean body
mass index 23.8 ± 2.8 kg/m2. Sixty-eight
percent of the patients were males and 64%
were white. The most frequent causes of
end-stage renal disease were chronic glo-
merulonephritis (22%), hypertension (22%)
and diabetes (8%) and these patients had
been on hemodialysis for a mean time of 21.0
± 16.6 months. Mean human leukocyte anti-
gen (HLA) mismatch was 3.3 ± 1.0 and the
vast majority of the patients (96%) had
reactive antibody panel of less than 5%. All
patients were hepatitis B and C negative and
90% were cytomegalovirus positive. Except
for older age and mean HLA mismatch, no
other significant differences were observed
in baseline demographic characteristics be-
tween patients receiving sirolimus or AZA
(Table 1).
Immunosuppression and monitoring
Mean CsA dose (week 4 to week 52,
Figure 1A) and blood concentrations (week
12 to week 52, Figure 1B) were significantly
lower among patients receiving sirolimus.
However, there were no significant differ-
ences in dose-normalized CsA concentra-
tions between groups (data not shown).
Mean trough whole blood sirolimus concen-
trations were 5.2 ± 3.1 at day 7, 7.5 ± 3.6 at
week 4, 7.9 ± 4.1 at week 8, 8.2 ± 4.2 at week
12, 7.8 ± 4.5 at week 24, and 8.4 ± 6.0 at
week 52 (Figure 2). Mean sirolimus concen-
trations significantly increased from week 1
to week 16 (5.2 ± 3.1 vs 9.8 ± 5.7, P <
0.0001). Mean individual sirolimus concen-
trations showed a 10-fold variation from 2.5
to 23.5 ng/ml. Prednisone taper was faster in
patients receiving sirolimus (week 4: 24.2 ±
8.7 vs 27.1 ± 5.36, P = 0.062; week 8: 14.5
Table 1. Demographic characteristics of the transplant population.
Total Sirolimus Azathioprine P value
(N = 125) (N = 90) (N = 35)
Age (years) 38.1 ± 10.8 40.0 ± 10.4 33.2 ± 10.5 0.001
(15.0-63.0) (19.0-63.0) (15.0-58.0)
Gender (male/ 85 (68)/40 (32) 61 (68)/29 (32) 24 (69)/11 (31) 1.000
female)
Weight (kg) 64.9 ± 9.6 65.1 ± 9.9 64.4 ± 9.0 0.739
(32.1-89.0) (32.1-89.0) (46.8-87.7)
Body mass index 23.8 ± 2.8 23.9 ± 3.2 23.6 ± 1.6 0.680
(kg/m2) (12.2-31.5) (12.2-31.5) (20.8-25.7)
Ethnicity
White 80 (64) 58 (64) 22 (63) 0.874
Black 20 (16) 13 (14) 7 (20)
Mulate 21 (17) 16 (18) 5 (14)
Others 4 (3) 3 (4) 1 (3)
Cause of ESRD
Hypertension 22 (18) 18 (20) 4 (11) 0.068
Chronic 28 (22) 14 (16) 14 (40)
glomerulonephritis
Diabetes mellitus 10 (8) 9 (10) 1 (3)
Nephrosclerosis 6 (5) 4 (4) 2 (6)
Others 59 (17) 45 (50) 14 (40)
Viral status
Anti-HCV positive 0 (0)/125 (100) 0 (0)/90 (100) 0 (0)/35 (100) 1.000
(IgG)
HbsAg positive 0 (0)/125 (100) 0 (0)/90 (100) 0 (0)/35 (100) 1.000
CMV positive (IgG)    112 (90)/13 (10) 82 (91)/8 (9) 30 (86)/5 (14) 0.514
Time on dialysis 21.0 ± 16.6 22.4 ± 17.2 20.4 ± 14.1 0.223
(months) (2.0-75.0) (2.0-75.0) (3.0-58.0)
HLA mismatchs 3.3 ± 1.0 3.4 ± 1.2 2.8 ± 0.5 0.003
(2.0-6.0) (2.0-6.0) (2.0-4.0)
Reactive antibody 120 (96)/5 (4) 88 (98)/2 (2) 32 (91)/3 (9) 1.000
panel (<5%/≥5%)
Donor age (years) 42.8 ± 9.9 42.8 ± 10.0 42.9 ± 9.9 0.970
Delayed graft 6.4 5.6 8.6 0.685
function (%)
Data are reported as mean ± SD (range). CMV = cytomegalovirus; ESRD = end-stage
renal disease; HCV = hepatitis C virus; HLA = human leukocyte antigen.
*P < 0.05 for sirolimus vs azathioprine (unpaired Student t-test for continuous and
chi-square test for categorical variables).
1308
Braz J Med Biol Res 37(9) 2004
P.G.P. Machado et al.
20% in the AZA group. The incidence of
biopsy-proven acute rejection was 14.4%
(13/90) and 14.3% (5/35). Sirolimus treat-
ment delayed the time to first biopsy-proven
acute rejection (119.8 ± 108.4 vs 6.2 ± 2.6
days, P = 0.05). There were 3 graft losses,
2 in the sirolimus group (recurrence of seg-
mental and focal glomerulosclerosis, persist-
ent urinary fistula) and 1 in the AZA group
(recurrence of segmental and focal glomer-
ulosclerosis). There were 4 deaths, 3 in the
sirolimus group (sepsis, cerebrovascular
hemorrhage, sudden death) and 1 in the AZA
group (sudden death) (Table 2).
Safety
There were 17 (14%) treatment discon-
tinuations, 14 in the sirolimus group (16%)
and 3 in the AZA group (9%). In the sirolimus
group, 4 patients were switched from CsA to
tacrolimus after an acute rejection episode.
Due to adverse events, CsA was discontin-
ued in one patient with hemolytic uremic
syndrome, and sirolimus was discontinued
in 9 patients (3 cases of hyperlipidemia, 2 of
acute tubular necrosis, 2 of anemia, 1 case of
graft dysfunction, and 1 case of sepsis). In
the AZA group, CsA was discontinued in one
patient with early and rapidly progressive
recurrence of segmental and focal glomeru-
losclerosis. AZA was discontinued in 2 pa-
tients due to hepatotoxicity and severe cy-
tomegalovirus infection (Table 2).
Graft function
At 12 months, protocol population con-
sisted of 105 patients, 74 in the sirolimus
group and 31 in the AZA group, which was
considered for the analysis of graft function.
Twenty patients were excluded, including 17
drug discontinuations and 3 deaths. There
were no significant differences in baseline
demographic characteristics between the
intention-to-treat and per-protocol popula-
tion. Comparing patients receiving sirolimus
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Figure 1. Mean cyclosporine daily doses (A) and trough whole blood concentrations (B) in
patients receiving sirolimus (squares) or azathioprine (circles). *P < 0.05 comparing mean
values at each time of transplant (unpaired Student t-test).
± 5.3 vs 19.93 ± 3.71, P = 0.001; week 12:
10.9 ± 2.7 vs 14.50 ± 4.36, P = 0.006). Mean
AZA doses were 126.4 ± 30.3 and 116.1 ±
30.7 mg at week 1 and 52, respectively.
Efficacy
Twelve-month composite efficacy failure
(biopsy-confirmed acute rejection, graft loss
or death) was 18% in the sirolimus group and
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or AZA, at 3 months there were no differ-
ences in mean creatinine values (1.46 ± 0.35
vs 1.44 ± 0.34 mg/dl) or mean creatinine
clearances (65 ± 16 vs 65 ± 14 ml/min). At
6 months, patients receiving AZA showed
lower mean serum creatinine (1.62 ± 0.43 vs
1.45 ± 0.34 mg/dl, P = 0.045) and higher
mean calculated creatinine clearance (62 ±
17 vs 65 ± 17 ml/min, P = 0.02) but at 12
months there were no differences in mean
creatinine (1.65 ± 0.46 vs 1.60 ± 0.43 mg/dl)
or calculated creatinine clearance (61 ± 15 vs
62 ± 13 ml/min, P = 0.58) (Figures 3 and 4).
At 12 months, mean ∆1/Cr did not differ
between the AZA and sirolimus groups (-11
± 17 vs -14 ± 15%, P = 0.7). The percentage
of patients with ∆1/Cr higher than -20% (26
(8/31) vs 31% (23/75), P = 0.6) or higher
than -30% (19 (6/31) vs 17% (13/75), P = 1)
also did not differ. Multiple linear regression
analysis showed no significant correlations
between blood CsA concentrations at 1
month, at 3 months, mean individual sirolimus
concentrations and graft function measured
by creatinine, calculated creatinine clear-
ance, and ∆1/Cr. There were no correlations
between the mean individual sirolimus con-
centrations divided into quartiles (≤6 ng/ml,
6.1-7.7 ng/ml, 7.8-9.5, and >9.5 ng/ml) and
graft function at one year.
Discussion
Acute rejection and graft function at one
Figure 2. Trough whole blood
sirolimus concentrations during
the first year after transplanta-
tion. Middle horizontal thick bar
is the median; the top and bot-
tom square lines indicate the
75th and 25th percentiles; the
error bars denote the limits of
the 90th and 10th percentiles;
open circles are outliers. *P =
0.012 (ANOVA, week 1 through
week 16).
Figure 3. Serum creatinine con-
centrations in patients receiv-
ing sirolimus or azathioprine
during the first year after trans-
plantation. The middle horizon-
tal thick bar is the median; the
top and bottom square lines
indicates the 75th and 25th
percentiles; the error bars de-
note the limits of the 90th and
10th percentiles; open circles
are outliers. P > 0.05 compar-
ing sirolimus and azathioprine
values on the occasion of each
visit (unpaired Student t-test).
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Table 2. Efficacy and safety analysis one year after kidney transplantation.
Parameters - N (%) Total (N = 125) Sirolimus (N = 90) Azathioprine (N = 35)
Composite end-point 23 (18.4) 16 (17.8) 7 (20.0)
Biopsy-confirmed acute rejection 18 (14.4) 13 (14.4) 5 (14.3)
BANFF (IA/IB/IIA/IIB/III) 8/4/6/0/0 6/3/4/0/0 2/0/2/0/1
Graft loss 3 (2.4) 2 (2.2) 1 (2.9)
Death 4 (3.2) 3 (3.3) 1 (2.9)
Study drug discontinuation 17 (13.6) 14 (15.5) 3 (8.6)
Lack of efficacy 4 (3.2) 4 (4.4) 0 (0.0)
Adverse event 13 (10.4) 10 (11.1) 3 (8.6)
There was no significant difference between sirolimus vs AZA for any of the parameters (chi-square test).
year are good predictors of late kidney graft
loss (4,15). Therefore, the benefit of the
combination of sirolimus with full doses of
CsA in reducing the incidence of acute rejec-
tion might be counterbalanced by the im-
paired graft function seen at one year in
patients receiving this drug combination (1,2).
Here we demonstrate that reduction of CsA
dose, beginning 4 weeks after transplanta-
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tion, was effective in maintaining a low
incidence of acute rejection rate while im-
proving one-year graft function, which was
similar to that seen in the control group of
patients receiving AZA, in contrast to the
findings of the phase III clinical trials in
which patients receiving the CsA and sirolimus
combination showed impaired graft function
compared to patients receiving CsA and AZA
(1).
Efficacy as well as safety analysis showed
that the immunosuppressive strategy resulted
in comparable incidences of acute rejection
rates when full CsA doses were used in
multicenter trials (1,2), and that tolerability
was very good with only 11% of patients
discontinuing CsA or sirolimus due to an
adverse event. It is important to point out that
the entire population consisted of recipients
of living donor allografts, minimizing the
influence of brain death, donor injury, ische-
mia, preservation and reperfusion injuries,
and delayed graft function on one-year graft
function. Moreover, the very low incidence
of biopsy-confirmed acute rejection rate in
the AZA group was unexpected, perhaps
related to the small sample size since our
historical and current acute rejection rates
are about 30%, reducing the impact of acute
rejection on one-year graft function in this
group of patients.
The doses of CsA were reduced by 18%
at week 4, reaching 35% at week 52. This
resulted in an 11% and 51% reduction in CsA
concentrations at weeks 4 and 52, respec-
tively. Dose-normalized CsA concentrations
did not differ between sirolimus and AZA
patients, suggesting that the doses used in
this study did not produce significant phar-
macokinetic interaction between sirolimus
and CsA in the blood compartment. Blood
sirolimus concentrations increased progres-
sively from week 4 to week 16 (Figure 2).
During this period CsA concentrations were
reduced by about 25% compared to AZA
patients, and significant differences were
observed in graft function at 24 weeks (Fig-
ures 3 and 4). A further 25% reduction in
CsA concentrations from week 24 to 52
resulted in an improvement of graft function
at one year. Mean individual sirolimus con-
centrations or CsA concentrations at 1 and 3
months showed no linear relationship with
graft function. Even when mean individual
sirolimus concentrations were divided into
quartiles, no relationship with graft function
was observed. Since we were using 2-mg
fixed doses of sirolimus and were not aware
of blood sirolimus concentrations, we were
unable to reduce the dose of CsA even
further, which might have resulted in addi-
tional improvement in graft function at one
year.
Recently, the use of therapeutic sirolimus
monitoring has allowed safer, earlier, and
higher reduction in CsA exposure, providing
the opportunity to design protocols that may
result in better kidney graft function (16). In
one study 309 patients showing therapeutic
sirolimus concentrations (5-15 or 10-20 ng/
ml) were randomized to full (150-300 ng/ml)
or reduced (50-125 ng/ml) CsA exposures 3
months after transplantation, respectively.
There were no significant differences in
biopsy-confirmed acute rejection (10.5 vs
12.6%) or graft function at 6 months (1.69
vs 1.58 mg/dl) (17). In another study 400
patients were randomized to receive full or
reduced CsA exposures. At 6 months, pa-
tients in both groups showed mean sirolimus
concentrations of 9.1 ng/ml and mean CsA
Figure 4. Calculated creatinine
clearances by patients receiving
sirolimus or azathioprine. The
middle horizontal thick bar is the
median; the top and bottom
square lines indicates the 75th
and 25th percentiles; the error
bars denote the limits of the
90th and 10th percentiles. *P <
0.05 comparing sirolimus and
azathioprine at each time (un-
paired Student t-test).
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concentrations of 165.3 and 104.9 ng/ml,
respectively. Again, there were no signifi-
cant differences in biopsy-confirmed acute
rejection (5.6 vs 10%) or graft function at 6
months (2.03 vs 1.78 mg/dl) (18).
An interesting finding was that mainte-
nance of lower CsA exposures did not in-
crease the proportion of patients showing
higher than -20 or -30% ∆1/Cr, suggesting
that there was no increase in the rate of graft
function deterioration from 3 to 12 months
compared to patients receiving AZA. Taken
together, these results suggest that the ad-
ministration of initial full doses of cyclo-
sporine for 1 to 3 months, even when fol-
lowed by subsequent dose reduction or with-
drawal, may produce significant and prob-
ably irreversible kidney graft damage. These
assumptions are supported by the results of
trials in which patients receiving sirolimus-
based immunosuppressive regimens showed
better graft function at one year, with mean
creatinine values of 1.31 mg/dl (115.8 µM)
using the combination of sirolimus and aza-
thioprine (19), 1.45 mg/dl (128.3 µM) using
the combination of sirolimus and myco-
phenolate mofetil (20), and 1.32 mg/dl using
the combination of basiliximab, sirolimus
and mycophenolate mofetil (21). Also, pro-
gressively lower acute rejection rates, 41,
27.5 and 6.4%, were seen in this three latter
trials, respectively. The analysis of all these
studies suggests that complete avoidance of
CsA and low rejection rates seem to be
associated with better graft function at one
year and perhaps with increased long-term
graft survival. On the other hand, while
during treatment with the sirolimus/CsA com-
bination withdrawal of steroids appears to be
safe (22), there are no data about the safety
of this strategy in patients using sirolimus-
based immunosuppressive therapies. Cur-
rently, in this cohort of patients, 42% of
patients in the sirolimus group were not
treated with steroids for a mean follow-up
time of 201 ± 265 (93-648) days. If reduced
acute rejection rates and good graft function,
produced by new, although more expensive,
immunosuppressive drugs, in fact translate
into prolonged long-term graft survival com-
pared to the old cyclosporine, azathioprine,
and prednisone combination, then we may
say that this new regimens will also be cost-
effective. Nevertheless, large and prospec-
tive clinical trials will be needed to assess the
long-term efficacy and safety of calcineurin
inhibitor avoidance and steroid withdrawal
immunosuppressive regimens (23).
We conclude that in low risk recipients of
living kidney transplants the use of 2-mg
fixed doses of sirolimus and prednisone,
with early reduction in CsA exposure was
effective, safe and preserved graft function
at one year compared to patients receiving
AZA. Improvements in the use of sirolimus/
CsA combinations using therapeutic drug
monitoring may allow even earlier and fur-
ther reduction CsA exposure, a potential
strategy to improve long-term patient and
graft outcomes.
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